BYSI BeyondSpring

BeyondSpring Files 2019 Annual Report on Form 20-F

BeyondSpring Files 2019 Annual Report on Form 20-F

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission (“SEC”) on April 30, 2020. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at and on the Company’s website at under “Financials & Filings” in the Investors section.

The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.

About BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, first in class agent Plinabulin as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.

Contact:

Media & Investor Relations :

Jeffrey Goldberger / Caitlin Kasunich

KCSA Strategic Communications

212.896.1249 / 212.896.1241

/

EN
30/04/2020

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at , taking place on May 30 through June 3 in Chicago, IL. ​​Presentation de...

May 28, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides...

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutic...

May 12, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Files 2024 Annual Report on Form 10-K

BeyondSpring Files 2024 Annual Report on Form 10-K FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at and on the Company...

March 27, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Ke...

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED T...

March 27, 2025 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Inter...

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of (“SEED”), a biotechnology company focused on Targeted Protein Degradation (TPD) technology and a subsidiary of the...

January 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch